Ai-Ping. Zhou
机构：Chinese Academy of Medical Sciences & Peking Union Medical College, National Cancer Center
发表论文 2 篇 · 总被引 3 次 · h-index 1
代表论文
- Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial (2025 · Cancer Immunology Immunotherapy · 被引 3)
- P-246 Real-world outcomes in metastatic colorectal patients receiving regorafenib treatment in China (2022 · Annals of Oncology)